Scientific deep-dive
Which Weight-Loss Drug Works Best With Antipsychotics? What the Rankings Show
Five network meta-analyses rank drugs for antipsychotic weight gain, and they name three different leaders. Here is how semaglutide, liraglutide, metformin and topiramate compare, and how far to trust the order.
Semaglutide has the largest estimated effect in the most complete analysis so far: −10.98 kg against placebo across 95 studies in people with schizophrenia-spectrum disorders taking antipsychotics, on three semaglutide trials and moderate certainty evidence.[1] Metformin has a smaller estimate (−3.86 kg) but rests on 16 trials.[1] Earlier network analyses put liraglutide or metformin with lifestyle changes at the top,[4][5] and the authors of one 2026 analysis say the comparative ranking of the GLP-1 drugs “is uncertain.”[2] These comparisons are mostly indirect, so the order is a guide to questions for a prescriber and not a settled league table.
About this article
This page compares the rankings and the non-GLP-1 options. For trial detail on semaglutide with clozapine or olanzapine, what happens after stopping, and the clozapine constipation warning, see our semaglutide and antipsychotic weight gain review. Nobody should stop or change an antipsychotic to lose weight without their psychiatrist.
Five network analyses, three different winners
A network meta-analysis estimates how treatments compare even when trials never tested them against each other, usually by linking them through placebo. That is why the same drugs can land in different orders as trials are added or grouped differently. The five analyses below were published between 2024 and 2026.[1][2][3][4][5]
| Analysis | Evidence base | Leading result | Note |
|---|---|---|---|
| Hegde, Gen Hosp Psychiatry 2024 | 68 trials, Bayesian | Metformin 750 mg + lifestyle −7.5 kg named most effective | Sibutramine 10 mg had the largest estimate, −8.0 kg |
| Goetz-Kundera, Compr Psychiatry 2025 | 27 studies, 17 drugs | Liraglutide −5.3 kg beyond 12 weeks; first by SUCRA | Authors favor metformin and liraglutide |
| Mansour, J Psychopharmacol 2026 | 55 trials, 2,977 people, search to July 2025 | Semaglutide −13.5 kg vs usual care | Metformin + NutriEx −6.34 kg second |
| Stogios, JAMA Psychiatry 2026 | 95 studies, 39 drugs, 5,898 people, search to Dec 2025 | Semaglutide −10.98 kg vs placebo | Moderate certainty for the top five |
| Kishi, Transl Psychiatry 2026 | 9 trials, 595 people, GLP-1 drugs only | Semaglutide SMD −2.101 vs control | 83.9% schizophrenia-spectrum; liraglutide SMD −0.945; exenatide not reported as significant |
Three things explain most of the movement. The first is timing. The semaglutide trials were published from mid-2025 onward,[6][7][8] and the two earlier analyses do not list semaglutide among their significant results, likely because few or none of those trials were available to them.[4][5]
The second is how treatments are split. Hegde analyzed each dose separately, which produced metformin 750 mg at −5.7 kg and metformin 1,000 mg at −2.3 kg.[5] A lower dose beating a higher one may reflect which small trials sit behind each estimate. The same paper put sibutramine at the top on point estimate, with an interval running from −16 to −0.21 kg.[5] Sibutramine is not an option in the US: the FDA says it was withdrawn from the market in December 2010 after data showed increased risk of heart attack and stroke.[18]
The third is thin evidence at the top. Kishi’s authors say semaglutide “may be the preferred treatment option” but that its ranking is uncertain “due to sparse networks, substantial heterogeneity, and predominant indirect evidence.”[2] Note that Kishi’s figures are standardized mean differences, a unitless measure, and cannot be read as kilograms.
The top five, and how much is behind each
Stogios gives the fullest picture, so its numbers anchor the table below, alongside other estimates for the same drugs. All five were rated moderate certainty in that analysis. Only semaglutide and metformin reached the 5% weight change the authors treated as clinically meaningful.[1] Read differences between rows as numerically larger or smaller, not as proven gaps: these abstracts report each drug against placebo or usual care, not against the others.
| Drug | Stogios 2026 | Trials behind it | Another estimate |
|---|---|---|---|
| Semaglutide | −10.98 kg (−13.33 to −8.62) | 3 | −13.5 kg vs usual care (Mansour) |
| Liraglutide | −5.43 kg (−8.54 to −2.33) | 2 | −5.3 kg beyond 12 weeks (Goetz-Kundera) |
| Topiramate | −3.95 kg (−5.89 to −2.02) | 5 | −4.82 kg for prevention, interval crosses zero (Cochrane) |
| Metformin | −3.86 kg (−5.02 to −2.70) | 16 | −3.32 kg, 20 studies (Peng) |
| Exenatide | −2.97 kg (−5.83 to −0.11) | 3 | −4.17 kg beyond 12 weeks (Goetz-Kundera) |
The comparison figures come from Mansour,[3] Goetz-Kundera,[4] the 2022 Cochrane review of prevention[12] and Peng.[11] Exenatide shows why a ranked list can mislead. It reaches significance in two network analyses,[1][4] yet Kishi lists only liraglutide and semaglutide as significant[2] and a pairwise review described its reduction as smaller and non-significant.[19]
What sits behind the semaglutide estimate
The Stogios abstract does not name its three semaglutide trials. Three placebo-controlled trials we read show how varied this small evidence base is.
- HISTORI: 154 Danish adults with schizophrenia, prediabetes and BMI of at least 27 took up to 1.0 mg weekly for 30 weeks. Weight fell 9.21 kg more than placebo. The primary outcome was HbA1c, and weight was a secondary endpoint.[7]
- Sass: 73 Danish adults who started clozapine or olanzapine within the past 5 years took 1 mg weekly for 26 weeks. Weight fell 9.2 kg more than placebo. The primary analysis was intention-to-treat on HbA1c, the authors call secondary outcomes exploratory, and 78% completed.[8]
- COaST: Australian adults on clozapine with BMI of at least 26 took semaglutide titrated to 2.0 mg for 36 weeks. The between-group difference was −13.46% of body weight, the primary outcome, analyzed with a mixed model for repeated measures in all randomized participants. Only 31 people were randomized against a target of 80, because the study drug became unavailable. It ran independently of industry support.[6]
Doses, durations and populations differ across these trials, which is part of what the word heterogeneity is pointing to. Pooled pairwise estimates for GLP-1 drugs as a group also show it: one 2026 review reports −6.54 kg with an I² of 92%,[9] and another reports −6.10 kg with an I² of 99% and low to moderate certainty.[10]
Options beyond the top five
Metformin
Metformin has the deepest evidence by trial count. A meta-analysis of 20 double-blind studies and 1,070 patients found −3.32 kg (95% CI −4.57 to −2.07) and reported that the effect held from 12 to 24 weeks.[11] Cochrane, looking at prevention of weight gain, rated its −4.03 kg estimate low certainty.[12] A broader view of the drug is in our metformin review.
Topiramate
Topiramate looks different depending on the question. It sits third in the Stogios treatment network,[1] while Cochrane’s prevention analysis of three studies found that it “did not appear effective,” with very low certainty.[12] For how the drug performs outside psychiatry, see our topiramate review.
Olanzapine with samidorphan
This combination pill is a different strategy: the data measure less gain on olanzapine, not loss of weight already gained. An individual patient data analysis of 1,063 people found a 3.68% gain at week 12 on the combination compared with 5.43% on olanzapine alone, a difference of −1.75%. Its authors include Alkermes employees.[14] A separate meta-analysis of four trials (1,416 people), whose authors declared no conflicts, found −1.18 kg and noted that naltrexone, another opioid-receptor blocker, did not separate from placebo.[13]
Smaller studies
Nizatidine shows up in several analyses, at −6.82 kg in short-term trials in one[4] and −5.46 kg in another,[3] but Stogios rates its evidence very low certainty.[1] In a 12-week trial of 84 adults on clozapine or olanzapine, empagliflozin and metformin did not differ significantly on weight; with no placebo arm, the trial cannot say how much either drug did on its own.[16] An 8-week orlistat trial of 60 people found a significant difference in BMI change and in some cholesterol measures, which is too short and small to place on a ranking.[17]
Tirzepatide: the gap
None of the network abstracts above reports a tirzepatide estimate. The closest data we found are observational. In a health-records study of 1,809 matched pairs with schizophrenia-spectrum disorders, tirzepatide use was associated with a lower composite of death, hospitalization and suicidal behavior (hazard ratio 0.66), with a hazard ratio of 0.18 for death alone.[15] The authors say control-outcome checks supported validity, but an association that large over one year could still partly reflect who gets prescribed a new drug. The abstract reports no weight outcome, so it cannot rank tirzepatide for weight. Any higher efficacy in people on antipsychotics would be an inference from other populations.
Side effects that travel with the ranking
Across the Stogios network there were “no major concerns” with gastrointestinal effects or dropouts between interventions.[1] Reviews limited to GLP-1 drugs show the class pattern more clearly. Pooling eight trials, one found higher risks of nausea (RR 1.61), vomiting (RR 2.10) and constipation (RR 2.34), no significant rise in serious adverse events (RR 0.72, 95% CI 0.49 to 1.06), and concluded that psychiatric safety “could not be established owing to sparse data.”[9] COaST saw no change in clozapine levels or PANSS symptom scores and low rates of constipation, in a trial of only 31 people.[6]
What to raise with a prescriber
- Which antipsychotic you take. Some trials enrolled only people on clozapine or olanzapine,[6][8] so results may not carry over evenly to other medicines.
- Whether the goal is preventing gain or losing weight. The Cochrane and samidorphan data address prevention,[12][14] while the Stogios network examines weight reduction.[1]
- Your blood sugar. The HISTORI and Sass trials selected for prediabetes or early glucose changes.[7][8]
- How constipation and other medicines will be monitored, particularly with clozapine, and who on your care team is in charge of that plan.
- How long treatment would last. The semaglutide trials above ran 26 to 36 weeks,[6][7][8] and one review calls for longer-term trials with standardized safety reporting.[9]
Frequently Asked Questions
References
- 1.Stogios N, Agarwal SM, Maksyutynska K, et al. Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. 2026. PMID: 42418179.
- 2.Kishi T, Ikuta T, Sakuma K, et al. Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis. Transl Psychiatry. 2026. PMID: 42420255.
- 3.Mansour MEM, Alsaadany KR, Mustafa MMM, et al. Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials. J Psychopharmacol. 2026. PMID: 41439550.
- 4.Goetz-Kundera Z, Przekopińska B, Walichniewicz P, et al. Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis. Compr Psychiatry. 2025. PMID: 40934730.
- 5.Hegde NC, Mishra A, Maiti R, et al. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis. Gen Hosp Psychiatry. 2024. PMID: 38878592.
- 6.Siskind D, Baker A, Arnautovska U, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025. PMID: 40506208.
- 7.Ganeshalingam AA, Uhrenholt N, Arnfred S, et al. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40900607.
- 8.Sass MR, Klausen MK, Schwarz CR, et al. Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 41335431.
- 9.Zhou L, Zhang Y, Shen C, Wu F. Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2026. PMID: 42920001.
- 10.Abbas N, Memon AA, Zulfiqar R, et al. Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2026. PMID: 42503999.
- 11.Peng TR, Chen JA, Lee JA, et al. The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis. Schizophr Bull. 2025. PMID: 39509416.
- 12.Agarwal SM, Stogios N, Ahsan ZA, et al. Pharmacological interventions for prevention of weight gain in people with schizophrenia. Cochrane Database Syst Rev. 2022. PMID: 36190739.
- 13.Lee K, Twohig M, Idoko NP, Williams BD. Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: A systematic review and meta-analysis of clinical trial data. J Psychopharmacol. 2025. PMID: 40406979.
- 14.Correll CU, Doane MJ, McDonnell D, et al. Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies. J Clin Psychiatry. 2025. PMID: 39832309.
- 15.Liu TH, Hsu CH, Wu JY, et al. Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients. Eur Neuropsychopharmacol. 2026. PMID: 41389474.
- 16.Dolati A, Ahmadimoghaddam D, Zamanirafe M, et al. Empagliflozin as an Alternative to Metformin for Antipsychotic-Related Weight Gain: Double-Blind Randomized Controlled Trial. Hum Psychopharmacol. 2026. PMID: 42135901.
- 17.Xie P, Shao T, Long Y, et al. Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial. Lipids Health Dis. 2024. PMID: 39049073.
- 18.US Food and Drug Administration. Questions and Answers about FDA's Initiative Against Contaminated Weight Loss Products. FDA. 2021. https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/questions-and-answers-about-fdas-initiative-against-contaminated-weight-loss-products
- 19.Sobral MVS, Menechini RB, Marçal JBC, et al. Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2026. PMID: 42497473.
Related research
Semaglutide for Antipsychotic Weight Gain: What the Clozapine and Olanzapine Trials Show
Semaglutide is now the best-studied add-on for antipsychotic weight gain. In two randomized trials of people on clozapine, olanzapine and similar drugs, it took off about 9 kg more than placebo without worsening symptoms. The trials, metformin and clozapine safety.
10 min read
GLP-1 Drugs and Eating Disorders: The 2026 Expert Consensus Explained
A 45-member panel in World Psychiatry advises screening before GLP-1 treatment and generally avoiding it in active eating disorders, particularly restrictive ones. Here is what it recommends, how thin the evidence is, and what it leaves out.
7 min read
GLP-1 With Lithium, Lamictal, or Atypical Antipsychotics
Atypical antipsychotics cause 5-15 kg weight gain on average. GLP-1 receptor agonists reverse this without affecting psychiatric stability. We review the published cohort data, the lithium PK + dehydration interaction, and the practical co-management protocol.
11 min read
Ozempic Drug Interactions: Common Medications and What Actually Matters
Can you take ibuprofen, Tylenol, antibiotics, or metformin with Ozempic? GLP-1 drug interactions explained: the real cautions vs the reassuring pharmacology.
10 min read
Metabolic Longevity: Do Anti-Aging Drugs & Supplements Actually Help Weight and Metabolism?
An evidence-first ranking of the popular 'metabolic longevity' interventions — GLP-1 agonists, metformin, berberine, NAD precursors, rapamycin, and senolytics — by how much human weight and metabolic evidence actually supports them, with a link to each fully-cited deep-dive.
6 min read
Do Weight-Loss Drugs Improve Natural Fertility? What the Meta-Analyses Show
GLP-1 therapy was linked to more natural pregnancies than metformin in PCOS trials, but pooled data are small, overall pregnancy did not differ significantly, and live birth benefit remains unproven. Here is what the reviews, orlistat trials and real-world records show.
7 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $199/mo
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $59/mo
+ required membership
CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $79/mo
“starting at” price